Drug intelligence / Profile preview

STX300

Development stage: Discontinued
Lead developer: SyntheX
Modality: Small Molecules

Overview

**STX300** is an investigational small molecule developed by SyntheX targeting oncogenic Ras GAPs (GTPase-activating proteins) for the treatment of neoplasms. It is part of SyntheX's pipeline focused on oncology, with potential involvement in protein degradation or modulation of Ras signaling pathways to inhibit tumor growth. The program was noted in scientific discussions around small G proteins and has reached a discontinued development status globally.[3][5][13]

Beyond the preview

Go deeper on STX300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STX300.

Explore the full profile